PATENT CLAIM ANALYSIS

Application Number: 16235210
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-07
Patent Classification: ["514", "345000"]

Abstract:
Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog.

Claim (Index 2):
The method of  claim 1 , wherein the interferon is selected from the group consisting of interferon alpha, interferon alpha-2a, recombinant interferon alpha-2a, peginterferon-alpha 2a, interferon alpha-2b, recombinant interferon alpha-2b, interferon alpha-2b XL, peginterferon alpha-2b, glycosylated interferon alpha-2b, interferon alpha-2c, recombinant interferon alpha-2c, interferon beta, interferon beta-1a, peginterferon beta-1a, interferon delta, interferon lambda, peginterferon lambda-1, interferon omega, interferon tau, gamma interferon, interferon alfacon-1, interferon alpha-n1, interferon alpha-n3, albinterferon alpha-2b, BLX-883, DA-3021, PEG-Infergen, and BELEROFON.

Metadata:
- Claim Count in Document: 42.0
- Percentile: 98.0
- Lexical Diversity: 1.70968
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14541487', '15671499', '14801126', '15284807', '15612240']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8449835479666594
- 35 USC 102 Novelty (BERT): 0.512719000412497
- Combined Prediction Score: 0.8117570932112432
- Mean Citation Score: 342.23141
- Max Citation Score: 345.6282
- Similarity Product: 339.5019845214128

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test